S3-Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin (DGEM) in Zusammenarbeit mit der Gesellschaft für klinische Ernährung der Schweiz (GESKES), der Österreichischen Arbeitsgemeinschaft für klinische Ernährung (AKE) und der Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)

 

 Permissions and Reprints

Zusammenfassung

Fragestellung: Die Bedeutung der Ernährung bei der Entstehung und Behandlung von chronisch-entzündlichen Darmerkrankungen (CED) wird teilweise kontrovers diskutiert. Klar ist, dass bei CED die Prävalenz von Mangelernährung erhöht ist und dass Mangelernährung die Prognose verschlechtert. In der vorliegenden Leitlinie werden evidenzbasierte Empfehlungen zur ernährungsmedizinischen Diagnostik und Therapie bei CED präsentiert.

Methodik: Die Leitlinie basiert auf den früheren Leitlinien der DGEM (2006/2007), der ESPEN (2006, 2009), der ECCO (2010) und des NICE (2012). Es wurde eine systematische Analyse der Literatur 2007 – 2013 zur oralen, enteralen und parenteralen Ernährung bei CED vorgenommen und gegenüber den früheren Leitlinien um die Themen Prävention und Screening von Malnutrition bei CED ergänzt. Die Empfehlungen wurden auf einer Konsensuskonferenz am 18.10.2013 verabschiedet.

Ergebnisse: Die Leitlinie umfasst 24 Empfehlungen zur Klinischen Ernährung bei CED. Screening auf Mangel- und Unterernährung sowie auf Mikronährstoffmangel wird bei CED empfohlen. Die Therapie der nachgewiesenen Malnutrition basiert auf Ernährungsberatung für eine bedarfsgerechte orale Ernährung und adäquater Ernährungstherapie. Neben Supplementen und oraler Trinknahrung kommen enterale und parenterale Ernährung als supplementäre Therapie infrage. Während die parenterale Ernährung nur in wenigen Sonderfällen meist passager durchgeführt wird, spielen die enterale Ernährung und orale Nahrungssupplemente eine bedeutsamere Rolle. Gerade bei Kindern wird die enterale Ernährung auch als primäre Therapie des akuten Schubs eines Morbus Crohn verwendet, um die unerwünschten Wirkungen von Medikamenten zu vermeiden.

Schlussfolgerung: Fachgerechte ernährungsmedizinische Diagnostik, Ernährungsberatung und enterale Ernährung spielen eine wichtige Rolle in der Behandlung von CED, sie können den Krankheitsverlauf sowie die Lebensqualität verbessern.

Abstract

Purpose: The importance of nutrition in the development and treatment of inflammatory bowel disease (IBD) is partially controversial. It is clear that in IBD, the prevalence of malnutrition is increased and that malnutrition worsens the prognosis. In the present guideline evidence-based recommendations for nutritional diagnostics and therapy in IBD are presented.

Methods: The guideline is based on the previous guidelines of DGEM (2006/2007), ESPEN (2006, 2009), ECCO (2010) and NICE (2012). We performed a systematic review of the literature 2007 – 2013 on oral, enteral and parenteral nutrition in IBD and we extended the earlier guidelines on the topics of prevention and screening of malnutrition in IBD. The recommendations were approved at a consensus conference on October 18th, 2013.

Results: The guideline includes 24 recommendations for clinical nutrition in IBD. Screening for malnutrition/undernutrition and micronutrient deficiency is recommended in IBD. The treatment of proven malnutrition is based on diet counseling for an appropriate oral nutrition and adequate nutrition therapy. In addition to micronutrient supplements and oral nutrition supplements enteral and parenteral nutrition are used as supplementary therapy. While parenteral nutrition is usually performed only in a few special cases, enteral nutrition as well as oral supplements play a significant role. Especially in children, enteral nutrition is also used as primary treatment of active Crohn’s disease in order to avoid the undesirable effects of drugs.

Conclusion: Professional nutritional diagnostics, dietary counseling and enteral nutrition play an important role in the management of IBD, they can improve the course of disease and quality of life.

^* DGEM Steering Committee: Bischoff SC, Lochs H, Weimann A sowie das DGEM-Präsidium.

• Literatur

• 1 Lochs H, Dejong C, Hammarqvist F et al. ESPEN Guidelines on Enteral Nutrition: Gastroenterology. Clin Nutr 2006; 25: 260-274
  CrossrefPubMedGoogle Scholar
• 2 Schulz RJ, Bischoff SC, Koletzko B et al. Gastroenterology – Guidelines on Parenteral Nutrition, Chapter 15. Ger Med Sci 2009; 7 Doc13
  PubMedGoogle Scholar
• 3 Van Gossum A, Cabre E, Hebuterne X et al. ESPEN Guidelines on Parenteral Nutrition: gastroenterology. Clin Nutr 2009; 28: 415-427
  CrossrefPubMedGoogle Scholar
• 4 Stingel K, Schütz T, Koller M et al. Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin (DGEM) – Methodik zum Leitlinien-Update Klinische Ernährung. Aktuel Ernahrungsmed 2013; 38: 90-96
  Google Scholar
• 5 Rigas A, Rigas B, Glassman M et al. Breast-feeding and maternal smoking in the etiology of Crohn’s disease and ulcerative colitis in childhood. Ann Epidemiol 1993; 3: 387-392
  CrossrefPubMedGoogle Scholar
• 6 Corrao G, Tragnone A, Caprilli R et al. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). Int J Epidemiol 1998; 27: 397-404
  CrossrefPubMedGoogle Scholar
• 7 Gearry RB, Richardson AK, Frampton CM et al. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol 2010; 25: 325-333
  CrossrefPubMedGoogle Scholar
• 8 Hansen TS, Jess T, Vind I et al. Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort. J Crohns Colitis 2011; 5: 577-584
  CrossrefPubMedGoogle Scholar
• 9 Koletzko S, Sherman P, Corey M et al. Role of infant feeding practices in development of Crohn’s disease in childhood. BMJ 1989; 298: 1617-1618
  CrossrefPubMedGoogle Scholar
• 10 Gilat T, Hacohen D, Lilos P et al. Childhood factors in ulcerative colitis and Crohn’s disease. An international cooperative study. Scand J Gastroenterol 1987; 22: 1009-1024
  CrossrefPubMedGoogle Scholar
• 11 Sonntag B, Stolze B, Heinecke A et al. Preterm birth but not mode of delivery is associated with an increased risk of developing inflammatory bowel disease later in life. Inflamm Bowel Dis 2007; 13: 1385-1390
  CrossrefPubMedGoogle Scholar
• 12 Klement E, Cohen RV, Boxman J et al. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 2004; 80: 1342-1352
  PubMedGoogle Scholar
• 13 van Rossum CTM, Büchner FL, Hoekstra J. Quantification of health effects of breastfeeding. Review of the literature and model situation. RIVM 2005; 350040001
  PubMedGoogle Scholar
• 14 Geerling BJ, Dagnelie PC, Badart-Smook A et al. Diet as a risk factor for the development of ulcerative colitis. Am J Gastroenterol 2000; 95: 1008-1013
  CrossrefPubMedGoogle Scholar
• 15 Larsen CS. Animal source foods and human health during evolution. J Nutr 2003; 133: 3893S-3897S
  PubMedGoogle Scholar
• 16 Hart AR, Luben R, Olsen A et al. Diet in the aetiology of ulcerative colitis: a European prospective cohort study. Digestion 2008; 77: 57-64
  CrossrefPubMedGoogle Scholar
• 17 Jantchou P, Morois S, Clavel-Chapelon F et al. Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study. Am J Gastroenterol 2010; 105: 2195-2201
  CrossrefPubMedGoogle Scholar
• 18 IBD in EPIC Study Investigators. Tjonneland A, Overvad K, Bergmann MM et al. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. Gut 2009; 58: 1606-1611
  CrossrefPubMedGoogle Scholar
• 19 Levo Y, Shalit M, Wollner S et al. Serum IgE levels in patients with inflammatory bowel disease. Ann Allergy 1986; 56: 85-87
  PubMedGoogle Scholar
• 20 Brignola C, Miniero R, Campieri M et al. Dietary allergy evaluated by PRIST and RAST in inflammatory bowel disease. Hepatogastroenterology 1986; 33: 128-130
  PubMedGoogle Scholar
• 21 D’Arienzo A, Manguso F, Astarita C et al. Allergy and mucosal eosinophil infiltrate in ulcerative colitis. Scand J Gastroenterol 2000; 35: 624-631
  CrossrefPubMedGoogle Scholar
• 22 Wyatt J, Vogelsang H, Hubl W et al. Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet 1993; 341: 1437-1439
  CrossrefPubMedGoogle Scholar
• 23 Katz KD, Hollander D, Vadheim CM et al. Intestinal permeability in patients with Crohn’s disease and their healthy relatives. Gastroenterology 1989; 97: 927-931
  PubMedGoogle Scholar
• 24 May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn’s disease?. Gastroenterology 1993; 104: 1627-1632
  PubMedGoogle Scholar
• 25 Ballegaard M, Bjergstrom A, Brondum S et al. Self-reported food intolerance in chronic inflammatory bowel disease. Scand J Gastroenterol 1997; 32: 569-571
  CrossrefPubMedGoogle Scholar
• 26 Mishkin S. Dairy sensitivity, lactose malabsorption, and elimination diets in inflammatory bowel disease. Am J Clin Nutr 1997; 65: 564-567
  PubMedGoogle Scholar
• 27 Lee J, Allen R, Ashley S et al. British Dietetic Association evidence-based guidelines for the dietary management of Crohn’s disease in adults. J Hum Nutr Diet 2013; DOI: 10.1111/jhn.12176. [Epub ahead of print]
  PubMedGoogle Scholar
• 28 Riordan AM, Hunter JO, Cowan RE et al. Treatment of active Crohn’s disease by exclusion diet: East Anglian multicentre controlled trial. Lancet 1993; 342: 1131-1134
  CrossrefPubMedGoogle Scholar
• 29 Candy S, Borok G, Wright JP et al. The value of an elimination diet in the management of patients with ulcerative colitis. S Afr Med J 1995; 85: 1176-1179
  PubMedGoogle Scholar
• 30 Sobotka L. Basics in Clinical Nutrition. 4th. ed., Prague: Galén; 2011
  Google Scholar
• 31 Kondrup J, Rasmussen HH, Hamberg O et al. Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr 2003; 22: 321-336
  CrossrefPubMedGoogle Scholar
• 32 Sousa Guerreiro C, Cravo M, Costa AR et al. A comprehensive approach to evaluate nutritional status in Crohn’s patients in the era of biologic therapy: a case-control study. Am J Gastroenterol 2007; 102: 2551-2556
  CrossrefPubMedGoogle Scholar
• 33 Valentini L, Schaper L, Buning C et al. Malnutrition and impaired muscle strength in patients with Crohn’s disease and ulcerative colitis in remission. Nutrition 2008; 24: 694-702
  CrossrefPubMedGoogle Scholar
• 34 Han PD, Burke A, Baldassano RN et al. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 423-443, ix
  CrossrefPubMedGoogle Scholar
• 35 Nguyen GC, Munsell M, Harris ML. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis 2008; 14: 1105-1111
  CrossrefPubMedGoogle Scholar
• 36 Kappelman MD, Bousvaros A. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res 2008; 52: 867-874
  CrossrefPubMedGoogle Scholar
• 37 Shamir R, Kolacek S, Koletzko S et al. Oral insulin supplementation in paediatric short bowel disease: a pilot observational study. J Pediatr Gastroenterol Nutr 2009; 49: 108-111
  CrossrefPubMedGoogle Scholar
• 38 Kugathasan S, Nebel J, Skelton JA et al. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr 2007; 151: 523-527
  CrossrefPubMedGoogle Scholar
• 39 Bager P, Befrits R, Wikman O et al. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scand J Gastroenterol 2011; 46: 304-309
  CrossrefPubMedGoogle Scholar
• 40 Roblin X, Phelip JM, Genevois M et al. Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohn’s disease. Aliment Pharmacol Ther 2007; 25: 797-804
  CrossrefPubMedGoogle Scholar
• 41 Vagianos K, Bector S, McConnell J et al. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr 2007; 31: 311-319
  CrossrefPubMedGoogle Scholar
• 42 Abitbol V, Roux C, Chaussade S et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 417-422
  CrossrefPubMedGoogle Scholar
• 43 Schulte C, Dignass AU, Mann K et al. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: 268-275
  PubMedGoogle Scholar
• 44 Lee TW, Kolber MR, Fedorak RN et al. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis 2012; 6: 267-275
  CrossrefPubMedGoogle Scholar
• 45 Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1545-1553
  CrossrefPubMedGoogle Scholar
• 46 Norman K, Kirchner H, Lochs H et al. Malnutrition affects quality of life in gastroenterology patients. World J Gastroenterol 2006; 12: 3380-3385
  PubMedGoogle Scholar
• 47 Lindor KD, Fleming CR, Ilstrup DM. Preoperative nutritional status and other factors that influence surgical outcome in patients with Crohn’s disease. Mayo Clin Proc 1985; 60: 393-396
  CrossrefPubMedGoogle Scholar
• 48 Higgens CS, Keighley MR, Allan RN. Impact of preoperative weight loss and body composition changes on postoperative outcome in surgery for inflammatory bowel disease. Gut 1984; 25: 732-736
  CrossrefPubMedGoogle Scholar
• 49 Aghdassi E, Wendland BE, Stapleton M et al. Adequacy of nutritional intake in a Canadian population of patients with Crohn’s disease. J Am Diet Assoc 2007; 107: 1575-1580
  CrossrefPubMedGoogle Scholar
• 50 Imes S, Pinchbeck B, Thomson AB. Diet counselling improves the clinical course of patients with Crohn’s disease. Digestion 1988; 39: 7-19
  CrossrefPubMedGoogle Scholar
• 51 Nagel E, Canzler H, Pichlmayr R. What is the role of nutrition in Crohn disease? A contribution to the importance of dietary therapy in regional enteritis. Langenbecks Arch Chir 1991; 376: 238-246
  PubMedGoogle Scholar
• 52 Bischoff SC, Fleig W. Ulcerative colitis. Nutrition. Z Gastroenterol 2004; 42: 998-1002
  PubMedGoogle Scholar
• 53 Weimann A, Breitenstein S, Breuer JP et al. S3-Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin (DGEM) in Zusammenarbeit mit der GESKES, der AKE, der DGCH, der DGAI und der DGAV: Klinische Ernährung in der Chirurgie. Aktuel Ernahrungsmed 2013; 38: 399-416
  PubMedGoogle Scholar
• 54 Rombeau JL, Barot LR, Williamson CE et al. Preoperative total parenteral nutrition and surgical outcome in patients with inflammatory bowel disease. Am J Surg 1982; 143: 139-143
  CrossrefPubMedGoogle Scholar
• 55 Gouma DJ, von Meyenfeldt MF, Rouflart M et al. Preoperative total parenteral nutrition (TPN) in severe Crohn’s disease. Surgery 1988; 103: 648-652
  PubMedGoogle Scholar
• 56 Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in inflammatory bowel disease: from A to zinc. Inflamm Bowel Dis 2012; 18: 1961-1981
  CrossrefPubMedGoogle Scholar
• 57 Lippuner K, Haller B, Casez JP et al. Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study. Miner Electrolyte Metab 1996; 22: 207-213
  PubMedGoogle Scholar
• 58 Jorgensen SP, Agnholt J, Glerup H et al. Clinical trial: vitamin D3 treatment in Crohn’s disease – a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010; 32: 377-383
  CrossrefPubMedGoogle Scholar
• 59 Pappa HM, Mitchell PD, Jiang H et al. Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens. J Clin Endocrinol Metab 2012; 97: 2134-2142
  CrossrefPubMedGoogle Scholar
• 60 Belluzzi A, Brignola C, Campieri M et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med 1996; 334: 1557-1560
  CrossrefPubMedGoogle Scholar
• 61 Lorenz-Meyer H, Bauer P, Nicolay C et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn’s disease. A randomized controlled multicenter trial. Study Group Members (German Crohn’s Disease Study Group). Scand J Gastroenterol 1996; 31: 778-785
  CrossrefPubMedGoogle Scholar
• 62 Feagan BG, Sandborn WJ, Mittmann U et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 2008; 299: 1690-1697
  CrossrefPubMedGoogle Scholar
• 63 Hawthorne AB, Daneshmend TK, Hawkey CJ et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992; 33: 922-928
  CrossrefPubMedGoogle Scholar
• 64 Romano C, Cucchiara S, Barabino A et al. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn’s disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol 2005; 11: 7118-7121
  PubMedGoogle Scholar
• 65 Manichanh C, Borruel N, Casellas F et al. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012; 9: 599-608
  CrossrefPubMedGoogle Scholar
• 66 Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009; 136: 2015-2031
  CrossrefPubMedGoogle Scholar
• 67 Inan MS, Rasoulpour RJ, Yin L et al. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology 2000; 118: 724-734
  CrossrefPubMedGoogle Scholar
• 68 Mallon P, McKay D, Kirk S et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (04) CD005573
  PubMedGoogle Scholar
• 69 Sood A, Midha V, Makharia GK et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1202-1209, 1209.e1
  CrossrefPubMedGoogle Scholar
• 70 Tursi A, Brandimarte G, Papa A et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105: 2218-2227
  CrossrefPubMedGoogle Scholar
• 71 Rolfe VE, Fortun PJ, Hawkey CJ et al. Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2006; (04) CD004826
  PubMedGoogle Scholar
• 72 Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94: 427-433
  CrossrefPubMedGoogle Scholar
• 73 Jonkers D, Penders J, Masclee A et al. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 2012; 72: 803-823
  CrossrefPubMedGoogle Scholar
• 74 Bousvaros A, Guandalini S, Baldassano RN et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 2005; 11: 833-839
  CrossrefPubMedGoogle Scholar
• 75 Steed H, Macfarlane GT, Blackett KL et al. Clinical trial: the microbiological and immunological effects of synbiotic consumption – a randomized double-blind placebo-controlled study in active Crohn’s disease. Aliment Pharmacol Ther 2010; 32: 872-883
  CrossrefPubMedGoogle Scholar
• 76 Van Gossum A, Dewit O, Louis E et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection. Inflamm Bowel Dis 2007; 13: 135-142
  CrossrefPubMedGoogle Scholar
• 77 Kruis W, Fric P, Pokrotnieks J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623
  CrossrefPubMedGoogle Scholar
• 78 Zocco MA, dal Verme LZ, Cremonini F et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1567-1574
  CrossrefPubMedGoogle Scholar
• 79 Sang LX, Chang B, Zhang WL et al. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol 2010; 16: 1908-1915
  CrossrefPubMedGoogle Scholar
• 80 Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309
  CrossrefPubMedGoogle Scholar
• 81 Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-1209
  CrossrefPubMedGoogle Scholar
• 82 Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2007; (01) CD000542
  PubMedGoogle Scholar
• 83 Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 2001; (03) CD000542
  PubMedGoogle Scholar
• 84 Fernandez-Banares F, Cabre E, Esteve-Comas M et al. How effective is enteral nutrition in inducing clinical remission in active Crohn’s disease? A meta-analysis of the randomized clinical trials. JPEN J Parenter Enteral Nutr 1995; 19: 356-364
  CrossrefPubMedGoogle Scholar
• 85 Griffiths AM, Ohlsson A, Sherman PM et al. Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology 1995; 108: 1056-1067
  CrossrefPubMedGoogle Scholar
• 86 Lochs H, Steinhardt HJ, Klaus-Wentz B et al. Comparison of enteral nutrition and drug treatment in active Crohn’s disease. Results of the European Cooperative Crohn’s Disease Study. IV. Gastroenterology 1991; 101: 881-888
  PubMedGoogle Scholar
• 87 Lochs H. To feed or not to feed? Are nutritional supplements worthwhile in active Crohn’s disease?. Gut 2006; 55: 306-307
  CrossrefPubMedGoogle Scholar
• 88 Critch J, Day AS, Otley A et al. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012; 54: 298-305
  CrossrefPubMedGoogle Scholar
• 89 Braegger C, Decsi T, Dias JA et al. Practical approach to paediatric enteral nutrition: a comment by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr 2010; 51: 110-122
  CrossrefPubMedGoogle Scholar
• 90 Werkstetter KJ, Schatz SB, Alberer M et al. Influence of exclusive enteral nutrition therapy on bone density and geometry in newly diagnosed pediatric Crohnʼs disease patients. Ann Nutr Metab 2013; 63: 10-16
  CrossrefPubMedGoogle Scholar
• 91 Soo J, Malik BA, Turner JM et al. Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohnʼs disease. Dig Dis Sci 2013; 58: 3584-3591
  CrossrefPubMedGoogle Scholar
• 92 Dziechciarz P, Horvath A, Shamir R et al. Meta-analysis: enteral nutrition in active Crohn’s disease in children. Aliment Pharmacol Ther 2007; 26: 795-806
  CrossrefPubMedGoogle Scholar
• 93 Borrelli O, Cordischi L, Cirulli M et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006; 4: 744-753
  CrossrefPubMedGoogle Scholar
• 94 El-Matary W. Enteral nutrition as a primary therapy of Crohn’s disease: the pediatric perspective. Nutr Clin Pract 2009; 24: 91-97
  CrossrefPubMedGoogle Scholar
• 95 Griffiths AM. Enteral feeding in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 2006; 9: 314-318
  CrossrefPubMedGoogle Scholar
• 96 Grogan JL, Casson DH, Terry A et al. Enteral feeding therapy for newly diagnosed pediatric Crohn’s disease: a double-blind randomized controlled trial with two years follow-up. Inflamm Bowel Dis 2012; 18: 246-253
  CrossrefPubMedGoogle Scholar
• 97 Heuschkel R, Salvestrini C, Beattie RM et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 839-849
  CrossrefPubMedGoogle Scholar
• 98 Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2007; (03) CD005984
  PubMedGoogle Scholar
• 99 Yamamoto T, Nakahigashi M, Umegae S et al. Enteral nutrition for the maintenance of remission in Crohn’s disease: a systematic review. Eur J Gastroenterol Hepatol 2010; 22: 1-8
  CrossrefPubMedGoogle Scholar
• 100 Verma S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish steroid dependency in Crohn disease?. Scand J Gastroenterol 2001; 36: 383-388
  CrossrefPubMedGoogle Scholar
• 101 Hirai F, Ishihara H, Yada S et al. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn’s disease in adults. Dig Dis Sci 2013; 58: 1329-1334
  CrossrefPubMedGoogle Scholar
• 102 Yamamoto T, Nakahigashi M, Umegae S et al. Prospective clinical trial: enteral nutrition during maintenance infliximab in Crohn’s disease. J Gastroenterol 2010; 45: 24-29
  CrossrefPubMedGoogle Scholar
• 103 Schneeweiss B, Lochs H, Zauner C et al. Energy and substrate metabolism in patients with active Crohn’s disease. J Nutr 1999; 129: 844-848
  PubMedGoogle Scholar
• 104 Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993; 88: 227-232
  PubMedGoogle Scholar
• 105 Harries AD, Jones LA, Danis V et al. Controlled trial of supplemented oral nutrition in Crohn’s disease. Lancet 1983; 1: 887-890
  PubMedGoogle Scholar
• 106 Belli DC, Seidman E, Bouthillier L et al. Chronic intermittent elemental diet improves growth failure in children with Crohn’s disease. Gastroenterology 1988; 94: 603-610
  PubMedGoogle Scholar
• 107 Mahajan L, Oliva L, Wyllie R et al. The safety of gastrostomy in patients with Crohn’s disease. Am J Gastroenterol 1997; 92: 985-988
  PubMedGoogle Scholar
• 108 Anstee QM, Forbes A. The safe use of percutaneous gastrostomy for enteral nutrition in patients with Crohn’s disease. Eur J Gastroenterol Hepatol 2000; 12: 1089-1093
  CrossrefPubMedGoogle Scholar
• 109 Jones BJ, Payne S, Silk DB. Indications for pump-assisted enteral feeding. Lancet 1980; 1: 1057-1058
  PubMedGoogle Scholar
• 110 Gassull MA. Review article: the role of nutrition in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20 (Suppl. 04) 79-83
  CrossrefPubMedGoogle Scholar
• 111 Sakurai T, Matsui T, Yao T et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn’s disease: a randomized, controlled trial comparing nutrient formulas. JPEN J Parenter Enteral Nutr 2002; 26: 98-103
  CrossrefPubMedGoogle Scholar
• 112 Khoshoo V, Reifen R, Neuman MG et al. Effect of low- and high-fat, peptide-based diets on body composition and disease activity in adolescents with active Crohn’s disease. JPEN J Parenter Enteral Nutr 1996; 20: 401-405
  CrossrefPubMedGoogle Scholar
• 113 Gassull MA, Fernandez-Banares F, Cabre E et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn’s disease: results of a double blind randomised multicentre European trial. Gut 2002; 51: 164-168
  CrossrefPubMedGoogle Scholar
• 114 MacLean CH, Mojica WA, Newberry SJ et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr 2005; 82: 611-619
  PubMedGoogle Scholar
• 115 Turner D, Shah PS, Steinhart AH et al. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. Inflamm Bowel Dis 2011; 17: 336-345
  CrossrefPubMedGoogle Scholar
• 116 Beattie RM, Schiffrin EJ, Donnet-Hughes A et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn’s disease. Aliment Pharmacol Ther 1994; 8: 609-615
  PubMedGoogle Scholar
• 117 Fell JM, Paintin M, Arnaud-Battandier F et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment Pharmacol Ther 2000; 14: 281-289
  CrossrefPubMedGoogle Scholar
• 118 Akobeng AK, Miller V, Stanton J et al. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn’s disease. J Pediatr Gastroenterol Nutr 2000; 30: 78-84
  CrossrefPubMedGoogle Scholar
• 119 Greenberg GR, Fleming CR, Jeejeebhoy KN et al. Controlled trial of bowel rest and nutritional support in the management of Crohn’s disease. Gut 1988; 29: 1309-1315
  CrossrefPubMedGoogle Scholar
• 120 Lochs H, Egger-Schodl M, Potzi R et al. Enteral feeding – an alternative to parenteral feeding in the treatment of Crohn disease?. Leber Magen Darm 1984; 14: 64-67
  PubMedGoogle Scholar
• 121 Lochs H, Meryn S, Marosi L et al. Has total bowel rest a beneficial effect in the treatment of Crohn’s disease?. Clin Nutr 1983; 2: 61-64
  PubMedGoogle Scholar
• 122 Elriz K, Palascak-Juif V, Joly F et al. Crohn’s disease patients with chronic intestinal failure receiving long-term parenteral nutrition: a cross-national adult study. Aliment Pharmacol Ther 2011; 34: 931-940
  CrossrefPubMedGoogle Scholar